SEC Comment Letter for GT Biopharma, Inc. (GTBP) (CIK 0000109657) (GTBP) — Jul 12, 2011
GT Biopharma, Inc. (GTBP) (CIK 0000109657)
Date: July 12, 2011 · CIK: 0000109657 · Accession: 0000000000-11-041962
AI Filing Summary & Sentiment
File numbers found in text: 000-08092
Show Raw Text
July 11, 2011 Anthony J. Cataldo Chief Executive Officer Oxis International, Inc. 468 N. Camden Drive Beverly Hills, California 90210 Re: Oxis International, Inc. Schedule 14A Filed July 1, 2011 File No. 000-08092 Dear Mr. Cataldo: We have limited our review of the above proxy statement to the issue identified below. Please respond to this letter by providing the requested information or by advising us when you will provide the requested response. If you do not believe our comment applies to your facts and circumstances, please te ll us why in your response. After reviewing the information you provide , we may have additional comments. 1. We note that your Board has unanimously adopted a resolution approving, declaring, advising and recommending to the stockholde rs for their approval an amendment to your certificate of inco rporation to effect a reverse stock split of your issued and outstanding common stock at any time pr ior to the next annual meeting of stockholders, at any whole number ratio of between 1-for-5 and 1-for-20, in the discretion of your Board. We also note your disclosure that the amendment to effect the reverse stock split will not change th e number of authorized shares of your common stock. Please disclose your curren t plans, arrangements or understandings, written or oral, to issue any of the shares that will be newl y available as a result of the approval of the reverse stock split. If you have no such plans, arrangements or understandings, please revise your disclosure to so state. We urge all persons who are responsible for th e accuracy and adequacy of the disclosure in the filing to be certain that the filing include s the information the Securities Exchange Act of 1934 and all applicable Exchange Act rules requir e. Since the company and its management are in possession of all facts relating to a company’s disclosure, they are responsible for the accuracy and adequacy of the disclosures they have made. In responding to our comment, please provide a written statement from the company acknowledging that: Anthony J. Cataldo Oxis International, Inc. July 11, 2011 Page 2 the company is responsible for the adequacy an d accuracy of the disclo sure in the filing; staff comments or changes to disclosure in response to staff comments do not foreclose the Commission from taking any action with respect to the filing; and the company may not assert staff comments as a defense in any proceeding initiated by the Commission or any person under the federa l securities laws of the United States. You may contact Johnny Gharib at (202) 551-3170 or me at (202) 551-3715 with any questions. Sincerely, /s/ Jeffrey Riedler Jeffrey Riedler Assistant Director